Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results GlobeNewswire May 08, 2025 Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral […]
Metsera to Present at Bank of America 2025 Global Healthcare Conference GlobeNewswire May 08, 2025 NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer,
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 GlobeNewswire May 08, 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi(R) Expected in the UK, EU, and Canada On Track to
(NASDAQ:SERV), Successfully built and deployed 250 new third-generation robots, enhancing operational scale and efficiency Continued geographic expansion into Miami and Dallas metros; Atlanta launch on track First quarter revenue of $440 thousand, a 150% increase versus Q4 2024 Unlocking the value of Serve's software and data platform; recurring revenue generation expected in Q2 Strengthened balance
(NasdaqGM:TKNO), First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze(TM) cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for
(NasdaqGM:TECX), Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the
(NasdaqGM:SKYE), Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonists
(NasdaqGM:CRVS), Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call
(NASDAQ:CODX), SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results: â— Revenue of $0.1 million, which declined from $0.5
(TSX:FM), TORONTO, May 08, 2025 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) announced that the nominees listed in the Management Information Circular for the 2024 Annual Meeting of Shareholders (the “Annual Meeting”) were elected as directors of First Quantum. In total, 715,082,417 shares were voted at the meeting,